Claims
- 1. A method for treating a bacterial infection in a human, said method comprising once-a-week or twice-a-week administration of rifalazil in a dosage of 1 to 100 mg.
- 2. The method of claim 1, wherein the dosage of rifalazil is 5 to 50 mg.
- 3. The method of claim 2, wherein the dosage of rifalazil is 10 to 25 mg.
- 4. The method of claim 1, wherein said rifalazil is administered for 4 to 52 weeks.
- 5. The method of claim 1 wherein the human is also administered erythromycin, clarithromycin isoniazid, ethambutol, pyrazinamide, streptomycin, capreomycin, ethlonamide, cyclosarine, kanamycin, tobramycin or amikacin.
- 6. The method of claim 1 wherein the rifalazil is administered orally, transdermally, parenterally, topically, by inhalation, or by suppositories.
- 7. The method of claim 5 wherein the parenteral administration is intravenously, intraperitoneally, subcutaneously or intramuscularly.
- 8. The method of claim 6 wherein the rifalazil is administered orally.
- 9. A method for treating a bacterial infection in a human, said method comprising once-a-week or twice-a-week administration of rifalazil in a dosage of 25-50 mg/week.
- 10. The method of claim 9, wherein the bacterial infection is infection caused by Mycobacterium tuberculosis, Mycobacterium avium complex, Chlamydia pneumoniae, or Hellcobacter pylori.
- 11. A method for treating a tuberculosis patient, said method comprising administering to said patient isoniazid daily and rifalazil once-a-week or twice-a-week.
- 12. A kit for treatment of bacterial infection in a human, comprising:a) a pharmaceutical composition comprising an active ingredient consisting of 25-50 mg rifalazil and a pharmaceutically acceptable excipient; and b) instructions directing a user to administer the pharmaceutical composition once-a-week or twice-a-week.
BACKGROUND OF THE INVENTION
This application is based on and is a continuation of 09/464,353 filed on Dec. 15, 1999, now U.S. Pat. No. 6,316,433 which claims priority of Provisional Application Serial No. 60/112,921 filed on Dec. 18, 1998.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
6316433 |
Rose et al. |
Nov 2001 |
B1 |
Non-Patent Literature Citations (2)
Entry |
Klemens et al., “Activity of KRM-1648 in combination with isoniazide aganist Mycobacterium tuberulosis in murine model”, Antimicrob. Agents Chemother. (1996), 40(2), 298-301.* |
Bermudez et al., “Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection”, Antimicrib. Agents Chemother. (1994), 38(8), 1844-1848. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/112921 |
Dec 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09/464353 |
Dec 1999 |
US |
Child |
09/972320 |
|
US |